主页

用于确定端粒长度的探针脊椎动物染色体的末端由重复的 TTAGGG 组成，称为端粒。这些端粒为 DNA 提供保护性末端帽，有助于保护潜在基因的完整性。在正常细胞分裂过程中，这些端粒会缩短，这个过程被认为与复制调节和细胞衰老有关。由于修复端粒的端粒酶的作用，某些细胞（例如生殖细胞、胎儿细胞和干细胞）保留了分裂的能力。人们认为癌细胞可以使用相同的机制来实现永生。因此，端粒长度的测定在癌症和年龄相关疾病的研究中具有重要意义。

端粒 PNA FISH 探针为 de使用荧光团标记的 PNA 探针通过荧光原位杂交 (FISH) 检测人类端粒序列。该方法提供了出色的定量结果，因为荧光强度与端粒的长度直接相关。下载 Panagene 的使用 PNA FISH 探针的方案参考：

Lansdorp PM, et al.人类染色体端粒长度的异质性。哼。摩尔。热内特。 1996;5:685-91Gabriela M. Baerlocher 等人。通过荧光原位杂交和流式细胞术测量端粒长度：技巧和陷阱。细胞计数 2002； 47:89–99

我们提供 5 纳摩尔数量的端粒探针 FISH 探针。 5 纳摩尔足以进行 100 次测试。所有探针的 HPLC 纯度都超过 95%。如需更大数量，请咨询。

显示所有 3 个结果

如需销售、报价和服务，请联系 CRB：

或者，您可以索取产品手册。

Acetyl-Leu-Ala-Thr-Lys-Ala-Ala-(ADMA)-Lys(Me)3-Ser-Ala-Pro-Ala-Thr-Gly-Gly-Val- Lys-Lys-Pro-His-Arg-Ahx-Lys(Biotin)-NH2

组蛋白的翻译后修饰（乙酰化、甲基化、磷酸化）改变它们与 DNA 的相互作用，并在多种生物过程中发挥作用，例如基因调控和 DNA 修复。随着甲基化精氨酸（单-、不对称二-和对称二-）和赖氨酸（单-、二-和三-）的商业引入，组蛋白肽的合成变得比以往任何时候都更加简单。使用最少量的不对称二甲基精氨酸和三甲基赖氨酸合成 C 端生物素化 H3 (20-40)。

H-Gly-Ala-[Tyr(pU-pU)]-Thr-Gly-Leu-Pro-Asn-Lys-Lys-Pro-Asn-Val-Pro-Thr-IIe-Arg-Thr -Ala-Lys-Val-Gln-OH

二尿酰化的 VPg（病毒蛋白基因组相关）肽 (VPgpUpU) 由 Fmoc SPPS 合成。酪氨酸的温和脱保护和充分保护的氨基磷酸酯的偶联，然后氧化和脱乙酰化/脱甲硅烷基化使得核肽的制备成为可能。

Poly-N-alkylated glycines（或 peptoids）是一个拟肽家族，其侧链附加到肽主链的氮原子上（与侧链位于 α-碳原子上的肽相比)（图 1.）。

这些化合物未在自然界中发现，但已被证明可以模仿，并且在某些情况下例，超过天然多肽的生物活性。此外，拟肽对蛋白水解降解具有抵抗力，并且能够采用稳定的螺旋结构。

拟肽的合成可以在固相上快速且相对便宜地进行，这使得拟肽在高和低分子中都具有吸引力-吞吐量筛选。图 2.（下图）说明了使用可完全自动化的亚单体方法 1 对通用拟肽进行固相组装。合成通过重复激活（酰化）/胺化步骤进行。

由于广泛的取代胺的商业可用性，拟肽的结构多样性可能是巨大的。

请联系我们获取根据您的要求设计的定制 peptoid 合成。

1.祖克曼等。阿尔。 J. 医学。化学。 1994, 37, 2678-2685.

Arg-Ser-Gly-Pro-Pro-Gly-{S-α-(4\'-戊烯丙氨酸)}-Gln-Gly-Arg- {S-α-(4 \'-戊烯丙氨酸)}-Gln-Arg-Leu-Leu-Gln-Ala-Ser-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Met-NH2

通过交联稳定螺旋是一种相对较新的方法，可用于设计高选择性肽。为了尽量减少用于闭环复分解反应的昂贵 Verdine 结构单元的数量，用 Grub 的催化剂处理了 40µmol 的肽基树脂。在装订之前和期间仔细控制肽的质量使得装订的 Orexin B 的产量很高。

Santa Clara, CA, April 15, 2009 — Cell Biosciences, Inc., a provider of innovative protein analysis tools to life science researchers, today announced the launch of two new platforms for ultrasensitive protein characterization. Both platforms will be unveiled at the American Association for Cancer Research (AACR) 101st Annual Meeting, April 17-21, 2010 in Washington, DC (booth 719).

The new NanoPro™ 100 system builds upon the success of the NanoPro CB1000 platform, which was introduced in 2009. The NanoPro CB1000 has been adopted by many of the worlds foremost drug development and translational medicine researchers, with nearly 30 systems placed in the past nine months. The NanoPro 100 offers the same analytical power as the high-throughput NanoPro CB1000 system, but in a compact, benchtop system designed for lower-throughput laboratories and individual investigators. The NanoPro 100 is the first system that gives researchers access to revolutionary NanoPro technology for under $100,000.

NanoPro assay technology enables detailed characterization of proteins in extremely small and precious samples, such as tumor micro-biopsies and isolated stem cell populations. NanoPro assays are used to uncover fundamental mechanisms controlling cell proliferation and cell death, to accelerate the development of new therapeutics, and to help identify new prognostic and diagnostic disease biomarkers. Current NanoPro customers include leading institutions and companies in the fields of cancer research, stem cell biology, diabetes, and drug development.

Also being launched at AACR 2010 is the FluorChem® E Digital Darkroom, which sets a new standard for high-performance chemiluminescent Western blot and gel imaging. The FluorChem E system features unparalleled sensitivity and resolution for Western blot analysis, and represents the first member of Cell Biosciences next-generation imaging product line. The systems innovative design incorporates state-of-the-art CCD technology and intuitive touch screen control for effortless analysis of chemiluminescent, colorimetric, and UV-fluorescent samples. FluorChem Es novel imaging software enables convenient file access from any internet-enabled device, such as Apples iPhone® or iPad™.

\"Cell Biosciences is committed to expanding its product leadership position in protein analysis,” commented Walter Ausserer, Ph.D., Vice President of Marketing at Cell Biosciences. \"We believe that customers will be delighted by the innovative features and exceptional performance of the NanoPro 100 and FluorChem E systems, and that these new platforms will be key drivers for our continued growth.”

Cell Biosciences is a private life sciences company focused on defining the future of protein analysis. The Company develops instrumentation systems, sample preparation systems, software and assay products that drive discoveries in fields ranging from fundamental protein research to biomarker discovery and personalized medicine. With an installed base of over 10,000 systems, its customers include leading research institutions, pharmaceutical and biotechnology companies worldwide. Cell Biosciences is headquartered in Santa Clara, California. For more information, visit www.cellbiosciences.com.
 

CONTACT: Walter Ausserer, Ph.D., Vice President of Marketing, Cell Biosciences, Inc., +1-408-510-5503, wausserer@cellbiosciences.com